Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 13/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.66 |
| ▸ | POLB | P06746 | 6/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.66 |
| ▸ | FABP4 | P15090 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 10/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | THRB | P10828 | 3/20 | 0.64 |
| ▸ | RECQL | P46063 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | ALPI | P09923 | 1/20 | 0.61 |
| ▸ | PIM1 | P11309 | 2/20 | 0.60 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8532185 | 1.00 | MEN1 (0.66) | MEN1KMT2APOLBGAAFABP4 | |
| SCHEMBL8582708 | 0.85 | MAPT (0.76) | MEN1KMT2APOLBGAAFABP4 | |
| SCHEMBL8582710 | 0.85 | MAPT (0.76) | MEN1KMT2APOLBGAAFABP4 | |
| SCHEMBL20558690 | 0.81 | FABP4 (0.81) | MEN1KMT2APOLBGAAFABP4 | |
| SCHEMBL19999119 | 0.81 | MEN1 (0.72) | MEN1KMT2APOLBGAAFABP4 | |
| SCHEMBL20558689 | 0.81 | FABP4 (0.81) | MEN1KMT2APOLBGAAFABP4 | |
| SCHEMBL20005693 | 0.81 | MEN1 (0.72) | MEN1KMT2APOLBGAAFABP4 | |
| SCHEMBL8708703 | 0.80 | MAPT (0.53) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL8708705 | 0.80 | MAPT (0.53) | MEN1KMT2APOLBMAPTALDH1A1 | |
| SCHEMBL18102925 | 0.80 | MEN1 (0.68) | MEN1KMT2APOLBGAAFABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | claimed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | claimed |
| EP-0434394-B1 | Compounds for treating inflammatory bowel disease | LILLY CO ELI (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5716975-A | NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1996022772-A1 | METHOD FOR TREATING MULTIPLE SCLEROSIS | ELI LILLY AND COMPANY (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5523314-A | RHODANINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
| US-5387690-A | Method of treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1995-02-07 | — | — | US | disclosed |
| US-5216002-A | Using benzyl substituted rhodanine derivatives as pure enantiomeric form | ELI LILLY AND COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0500337-A1 | Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes | UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-08-26 | — | — | EP | disclosed |
| EP-0434394-A2 | Compounds for treating inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |